Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

At Below $3 Clover Health Stock May Be Worth It as a Moonshot

By Thomas Niel, InvestorPlace Contributor

With CLOV stock, it may be worth rolling the dice at today's prices. 

Wait for Matterport Stock to Bottom Out Before Buying

By Thomas Niel, InvestorPlace Contributor

Matterport's spatial data business has high potential, but MTTR stock will continue to drop as meta-minded fair weather fans jump ship.

Even With Multi-Month Drop, It’s Too Early to Bottom-Fish QuantumScape Stock

By Thomas Niel, InvestorPlace Contributor

It's worth keeping an eye on it. It'll likely continue to make wild moves, in either direction. Yet until QS stock reaches the point where it's been truly oversold, it's best to hold off buying.

7 Penny Stock Bubbles That Are Bound to Burst

By Thomas Niel, InvestorPlace Contributor

Watch out with these seven penny stocks, a mix of plays that are still flying high, and a few that have already seen their bubble deflate.

Novavax Stock is in a Tough Spot, but its Fortunes Could Improve

By Thomas Niel, InvestorPlace Contributor

Once the vaccine maker starts booking big sales internationally, NVAX stock could make a trip back to much higher prices.

Load More